Phase 1 BA Study, Single Center With Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00870948

Enrollment

Registered

2009-03-27

Start date

2009-01-31

Completion date

Unknown

Last updated

2010-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Open Label, Healthy Volunteers

Brief summary

Single dose in healthy volunteers to assess bioavailability (amount of study drug in the system) between different formulations of ABT-874.

Interventions

DRUGABT-874

See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects must be healthy

Exclusion criteria

* Subjects who are not healthy, enrolled in another study, or who have received ABT-874 previously.

Design outcomes

Primary

Measure	Time frame
Bioavailability following single dose	Hours: 0, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 504, 672, 1008, 1344 for Regimens A, C, D and additional hours 4 & 8 for Regimen B and hours 0.5 and 6 hours for Regimen E

Secondary

Measure	Time frame
AEs, serious adverse events (SAEs), laboratory data, ADA and vital signs will be assessed throughout the study	Through Day 85 (and / or 45 days after study drug stoppped)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026